This economic evaluation estimates the cost-effectiveness of prevention strategies for ovarian and breast cancer among individuals with pathogenic variants in cancer susceptibility genes BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1. The gene discussed is PALB2; the disease is breast cancer.